Drug intelligence / Profile preview

SOXAP

Development stage: Preclinical
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

SOXAP is a multi-drug chemotherapy regimen primarily investigated for the treatment of gastric cancer. This regimen combines four distinct agents: S-1, an oral fluoropyrimidine derivative; oxaliplatin, a platinum-based chemotherapy drug; apatinib, an anti-angiogenic tyrosine kinase inhibitor; and camrelizumab, an immune checkpoint inhibitor. The combination aims to provide a comprehensive therapeutic approach by targeting cancer cells through various mechanisms, including DNA damage, antimetabolite action, inhibition of tumor angiogenesis, and activation of the immune system against cancer cells.

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA

Beyond the preview

Go deeper on SOXAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOXAP.

Explore the full profile